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Background: The simian malaria parasite Plasmodium knowlesi is now a well-recognized pathogen of humans in
South-East Asia. Clinical infections appear adequately treated with existing drug regimens, but the evidence
base for this practice remains weak. The availability of P. knowlesi cultures adapted to continuous propagation in
human erythrocytes enables specific studies of in vitro susceptibility of the species to antimalarial agents, and
could provide a surrogate system for testing investigational compounds against Plasmodium vivax and other
non-Plasmodium falciparum infections that cannot currently be propagated in vitro.
Objectives: We sought to optimize protocols for in vitro susceptibility testing of P. knowlesi and to contrast out-
puts with those obtained for P. falciparum under comparable test conditions.
Methods: Growth monitoring of P. knowlesi in vitro was by DNA quantification using a SYBR Green fluorescent
assay or by colorimetric detection of the lactate dehydrogenase enzyme. For comparison, P. falciparum was
tested under conditions identical to those used for P. knowlesi.
Results: The SYBR Green I assay proved the most robust format over one (27 h) or two (54 h) P. knowlesi life
cycles. Unexpectedly, P. knowlesi displays significantly greater susceptibility to the dihydrofolate reductase in-
hibitors pyrimethamine, cycloguanil and trimethoprim than does P. falciparum, but is less susceptible to the se-
lective agents blasticidin and DSM1 used in parasite transfections. Inhibitors of dihydroorotate dehydrogenase
also demonstrate lower activity against P. knowlesi.
Conclusions: The fluorescent assay system validated here identified species-specific P. knowlesi drug susceptibil-
ity profiles and can be used for testing investigational compounds for activity against non-P. falciparummalaria.
Introduction
One of six species of Plasmodium that infect humans, the zoonotic
parasite Plasmodium knowlesi is increasingly recognized as an
important contributor to malaria infection in South-East Asia,
including Malaysia, Myanmar and Indonesia.1–3 Infections are char-
acterized by the rapid (24 h) schizogonic cycle, can be severe and
are occasionally lethal. A thorough understanding of P. knowlesi
susceptibility to both existing and pipeline antimalarial therapies is
critical.
Thus far, in vitro screening of newly developed antimalarial
drugs has been limited to Plasmodium falciparum—the only tract-
able human malaria species in vitro until the recent adaptation of
P. knowlesi to continuous culture in human erythrocytes.4–6
Originally isolated from a Malaysian macaque in the 1960s, the
culture-adapted isolate has no history of exposure to antimalarial
drugs and provides an unselected genetic background on which to
screen new antimalarials by assessment of parasite susceptibility
in vitro. As early as 2004, incorporation of [3H]hypoxanthine was
used to monitor growth of P. knowlesi cultured in rhesus erythro-
cytes following exposure to selective agents used for transfection,7
and in human erythrocyte-adapted P. knowlesi cultures.8 Ex vivo
drug susceptibility has been investigated using the microscopy-
based WHO microtest and the colorimetric lactate dehydrogenase
(LDH) assay.9 All studies thus far have failed to address key differ-
ences in P. knowlesi biology that may reduce applicability of stand-
ard assays developed for P. falciparum. These include albumin
content of growth media, differences in life cycle length and con-
trasting multiplication rates. Thus meaningful, adequately
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controlled comparisons of in vitro drug susceptibility in the two
parasite species have yet to be reported.
We assess the susceptibility of P. knowlesi cultured in human
red cells against a panel of current and experimental antimalarial
agents, in comparison with drug-susceptible P. falciparum (3D7).
We evaluate assays using the DNA intercalating fluorescent dye
SYBR Green I, and the LDH-based colorimetric assay, to measure
parasite growth inhibition in vitro, and in so doing elucidate de-
tailed susceptibility profiles for several compound classes.
Materials and methods
Drugs
Antimalarial compounds were provided by the Medicines for Malaria
Venture, Geneva, Switzerland. Drug stocks were prepared in DMSO except
chloroquine and blasticidin, which were prepared in sterile distilled water.
Parasite culture
P. knowlesi (A1-H.1 clone) was cultured as described previously with minor
modifications.10 Briefly, parasites were maintained at 2% haematocrit in
RPMI 1640 supplemented with 25 mM HEPES, 25 mM Na2HCO3, 10 mM
D-glucose, 2 mM L-glutamine, 25 mg/L gentamicin sulphate, 50 mg/L hypo-
xanthine, 5 g/L Albumax II and 10% (v/v) equine serum (Thermo Fisher
Scientific, 26050-070). For routine culturing P. falciparum (3D7 clone) was
maintained in identical growth medium, supplemented with 2% heat-
inactivated human serum (Sigma–Aldrich, H4522) in place of the equine
serum. For drug assays, unless stated, both parasite species were grown in
the P. knowlesi growth medium/serum mix. Both P. knowlesi and P. falcip-
arum parasites were grown in human A! blood (National Health Blood and
Transplant, UK). Some experiments were performed in blood from Macaca
fascicularis, provided by NIBSC (UK) in K2EDTA vacutainers (Becton
Dickinson). Parasites were incubated at 37 C under a culture gas mixture of
93% N2, 4% CO2 and 3% O2.
Synchronization
P. knowlesi schizont culture was adjusted to 50% haematocrit in RPMI me-
dium; 2 mL was layered on top of 5 mL of 55% Nycodenz solution in 10 mM
HEPES (pH 7.0) and centrifuged at 900g for 12 min. The pigmented inter-
phase containing mature parasites was removed and washed in RPMI then
returned to culture with fresh red cells.6 P. falciparum parasites were
synchronized with 5% (w/v) D-sorbitol as described previously.11
Growth inhibition assays
Drug susceptibility of P. knowlesi and P. falciparum was assayed using
96-well flat-bottomed microplates, with 100lL of parasite stock added to
100lL of drug dilution in medium per well. Drug-free control wells were
included in each experiment and background fluorescence determined in
parasite-seeded wells containing a supralethal concentration of chloro-
quine (10lM). The plates were incubated at 37 C in an incubation chamber
(Billups-Rothenburg Inc.) under culture gas, and then stored at –20 C
overnight.
Microplates were thawed and incubated with 100lL of SYBR Green lysis
buffer [1:5000 SYBR Green I (Thermo Fisher Scientific, S7563), diluted in
20 mM Tris, 5 mM EDTA, 0.008% (w/v) saponin, 0.08% (v/v) Triton X-100, pH
7.5] in the dark for 1 h, before fluorescence was read in a Spectramax M3
microplate reader (Molecular Devices) at 490 nm excitation and 520 nm
emission.
The colorimetric LDH assay was performed as described for P. falciparum.12–15
Briefly, 100 lL of LDH lysis buffer [100 mM Tris–HCl, 200 mM L-lactic acid,
0.2% (v/v) Triton X-100, 125 lM 3-acetylpyridine adenine dinucleotide],
20 lL of nitroblue tetrazolium (1.6 mg/mL) plus phenazine ethosulphate
(80 lg/mL) solution and 20 lL of the resuspended parasite preparation
were added to each well of a duplicate plate. The plate was developed
in the dark for 30–60 min until a clear difference between drug-free con-
trols and background controls was apparent. Parasite growth is meas-
ured by accumulation of a blue formazan salt, giving absorbance at
650 nm.9,14,16
Time course
To test for the effect of parasite synchrony on drug responses, we initiated
a time course of drug susceptibility assays at 6 or 12 h intervals across the
P. knowlesi and P. falciparum life cycles of 27 and 48 h, respectively. Late-
stage parasites were synchronized with a 2 h window using sequential
Nycodenz purification as described previously.6 New ring stages (0–2 h
post-invasion) were diluted to 1% parasitaemia and exposed to drugs (as
described above) for one or two life cycles (27 or 54 h for P. knowlesi A1-
H.16 and 48 or 96 h for P. falciparum 3D7). From this parasite stock, subse-
quent drug assays on P. knowlesi were initiated every 6 h for 24 h and on P.
falciparumevery 12 h for 36 h.
Statistics
Z0 factors were calculated to measure the assay quality as described previ-
ously,17 using assay plates containing six negative control wells and six
positive control wells. Assays with Z0 values lying between 0.5 and 1.0 are
considered indicative of a robust assay performance. P values were calcu-
lated using Student’s two-tailed t-test for unpaired or paired samples.
Results and discussion
Effect of starting parasitaemia and haematocrit on
non-isotopic growth assays
Although previously used for parasite growth assay in
P. knowlesi,7,8,18 the requirement for radiolabelled hypoxanthine
and specialized equipment prevent the [3H]hypoxanthine incorp-
oration assay from being widely implemented. We therefore
focused our attention on optimization of two non-isotopic meth-
ods, namely the fluorometric SYBR Green I assay and the colori-
metric LDH enzyme assay, to measure and compare in vitro drug
susceptibility between P. knowlesi and P. falciparum.
P. knowlesi and P. falciparum parasites were diluted to a series
of starting parasitaemia at 1% haematocrit (Figure 1) or 2% haem-
atocrit (Figure S1, available as Supplementary data at JAC Online).
Whilst the P. knowlesi life cycle in vivo is 24 h, the life cycle in vitro
takes longer at 27 h, and incubation times were modified accord-
ingly. Cultures were therefore incubated in the presence or ab-
sence of drugs for one, two or three complete life cycles: 27, 54
and 81 h for P. knowlesi; 48 and 96 h for P. falciparum.
For P. knowlesi, the SYBR Green I assay produced high-quality
results for a single life cycle exposure (27 h) using a starting para-
sitaemia of 1% and 1% haematocrit (Figure 1a). Lower starting
parasitaemia also generated good-quality assays if exposed for
two (54 h) or three (81 h) life cycles. LDH assays starting at 1%
parasitaemia/1% haematocrit yielded assays of only borderline
quality and parasitaemia below 1% gave unsatisfactory results—
thus initiating assays at 2% parasitaemia is preferable for this
method (Figure 1b). The signal window improved with longer ex-
posures at all starting parasitaemia for the SYBR Green assay
(Figure 1e) and the LDH assay (Figure 1f) but remained ,3.0 for
both assay methods.
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For P. falciparum, good-quality assays were obtained at starting
parasitaemia of 0.25% and 1% haematocrit for a single life cycle
(48 h) and at 0.1% parasitaemia/1% haematocrit for two life cycles
(96 h) using the SYBR Green I method (Figure 1c). Similarly, the LDH
assay performed better with P. falciparum down to 0.25% starting
parasitaemia (Figure 1d). Again, the signal window improved with
higher initial parasitaemia and with longer exposures for both the
SYBR Green (Figure 1g) and LDH assays (Figure 1h). The species-
specific difference in assay quality for both formats is partly ex-
plained by the lower multiplication rate per life cycle for P. knowlesi
(3- to 4-fold) compared with P. falciparum (6- to 8-fold).
Furthermore, the activity of the LDH enzyme is poorly character-
ized in P. knowlesi relative to P. falciparum.
Effect of synchrony on drug susceptibility measured
across the life cycle
Drug susceptibility testing of P. falciparum is usually initiated using
sorbitol-synchronized ring-stage parasites. P. knowlesi is less
amenable to sorbitol synchronization, requiring density gradient
synchronization instead, and also loses synchrony rapidly in vitro.
To examine the effect of synchrony on susceptibility to antimalar-
ial agents, a time course was initiated with synchronized P. knowl-
esi or P. falciparum exposed to chloroquine, dihydroartemisinin or
pyrimethamine for one and two complete life cycles, and results
compared between the SYBR Green I fluorescence method (Figure
2) and the colorimetric method (Figure S2).
In the fluorescence assay after one cycle with P. knowlesi, the
initial life cycle stage had little effect on the EC50 for either the
endoperoxide dihydroartemisinin or the antifolate pyrimethamine,
but the EC50 varied dramatically with chloroquine (Figure 2a). For
P. falciparum there was relatively little variability in EC50 values for
chloroquine and dihydroartemisinin but large differences for pyri-
methamine after a single 48 h exposure (Figure 2c). For both spe-
cies, variability between EC50 values at different initial life cycle
stages was markedly reduced when samples were read after two
cycles (Figure 2b and d).
The fluorescence method yielded good Z0 factors of between
0.6 and 0.91 for P. knowlesi (Figure 2e and f) and between 0.75 and
0.89 for P. falciparum (Figure 2g and h), supporting the use of the
SYBR Green I method for assays initiated at 1% parasitaemia and
1% haematocrit on parasites of varying synchrony. For both spe-
cies, timing of initiation of the experiment and use of double life
cycle exposure were important determinants of quality (Figure 2f
versus e and Figure 2h versus g).
Synchronized assays read by the LDH method (Figure S2)
showed a similar pattern to those read for the fluorescence assay
after one cycle. Highly variable EC50 estimates were obtained with
chloroquine in P. knowlesi, and pyrimethamine in P. falciparum, de-
pending on the initial life cycle stage. For P. knowlesi, EC50 values
could not be obtained for pyrimethamine in 27 h experiments initi-
ated in early trophozoites (Figure S2A), even though estimates
were readily obtained using the SYBR Green I method (Figure 2a).
This suggests that short exposures of pyrimethamine were able to
inhibit DNA replication but not LDH activity in P. knowlesi. By the se-
cond life cycle exposure LDH activity was inhibited at higher drug
concentrations and all assays yielded EC50 values (Figure S2B).
Similarly, one of the P. falciparum curves for pyrimethamine failed
to yield an EC50 estimate after 48 h exposure but was able to gen-
erate data after 96 h exposure. This is clearly a weakness of
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Figure 1. Influence of starting parasitaemia of P. knowlesi (A1-H.1) and P. falciparum (3D7) on assay quality for both the fluorescent and colorimetric
methods. Parasites set to 1% haematocrit and varying parasitaemia (0.1%–2%) were cultured in the presence or absence of a supralethal concentra-
tion of chloroquine for 27 h (circles), 54 h (squares) or 81 h (diamonds) for P. knowlesi, and 48 h (cirlces) or 96 h (squares) for P. falciparum. Upon ter-
mination of the assay, the plates were read using either the SYBR Green I fluorescence assay (a, c, e and g) or the LDH assay (b, d, f and h). The signal
window and Z0 factor were calculated for each assay. The signal window was calculated by dividing the average reading for the drug-free control by
the average reading for the high chloroquine concentration (background) control. The assay quality was assessed by determining the Z0 factor using
the formula described in Zhang et al.17
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enzyme-based assays for measuring parasite growth and may
lead to otherwise active, potent compounds being incorrectly re-
jected if the timing or duration of exposure is non-optimal. As in
the previous assays, two-cycle experiments greatly reduced any
variation in EC50 caused by altering the initial life cycle stage.
Whilst the LDH assays performed on P. falciparum were of good
quality (Figure S2G and H), the assays on P. knowlesi performed
poorly with a small signal window and low Z0 factor after a single
life cycle (,2; Figure S2E). Signal and assay quality improved with
double life cycle exposure (Z0 range"0.51–0.77; Figure S2F). This
suggests that, for P. knowlesi, the LDH assay is not ideal for short-
exposure drug assays initiated at 1% parasitaemia and 1% haem-
atocrit. The LDH assay is suitable for P. falciparum drug assays but
caution is needed when examining the effect of antifolates such
as pyrimethamine. Although EC50 results for synchronous single-
cycle experiments varied dramatically depending on the initial life
cycle stage in P. knowlesi (Figure 2a), the mean EC50 obtained from
these synchronized assay data closely approximated the EC50 esti-
mates from experiments on non-synchronous parasites (Figure
S3). Thus, in addition to being logistically simpler, the non-
synchronous experiments can ameliorate the variation observed
due to stage-specific effects in synchronous experiments.
Considering this, and the variable performance of the LDH plat-
form, all subsequent susceptibility testing in P. knowlesi deployed
the non-synchronous fluorescent SYBR Green I method.
Activity of antimalarial agents
Using starting conditions of 1% parasitaemia and 1% haematocrit,
we compared the drug susceptibility of P. knowlesi and
P. falciparum (3D7) exposed for one complete life cycle. As
P. knowlesi requires media heavily supplemented with Albumax/
serum, all EC50 experiments were carried out in the P. knowlesi
media, which readily supports growth of both parasite species.
This removes the confounding effect of serum protein levels on
EC50 estimates for certain drugs (e.g. atovaquone; Table S1).
The susceptibility of P. knowlesi to the 4-aminoquinolines and
amino-alcohols was similar to that of P. falciparum (Table 1).
All EC50 estimates for P. knowlesi fell below 100 nM and within
2.5-fold of the EC50 reported for P. falciparum (Table 1). Although
the EC50 differences were not large between species, several
were statistically significant (P0.0424). Ferroquine, currently
in Phase II trials, was highly potent against P. knowlesi (12.2 nM;
Table 1).
Presently, artemisinin-based combination therapy is recom-
mended for the treatment of uncomplicated P. knowlesimalaria.19
Artesunate, dihydroartemisinin and a synthetic endoperoxide,
OZ439, were all highly potent against both parasite species, with P.
knowlesi significantly more susceptible to dihydroartemisinin than
P. falciparum (Table 1; P"0.0098).
Interestingly, we found P. knowlesi parasites to be highly sus-
ceptible to dihydrofolate reductase (DHFR) inhibitors, being more
than 9-fold more susceptible to pyrimethamine, cycloguanil and
trimethoprim than the drug-susceptible P. falciparum line tested
here. However, both species showed similar susceptibility (4 nM)
to the new DHFR inhibitor P218, designed to overcome resistant
forms of the P. falciparum enzyme.20 Thus existing medicines such
as sulfadoxine/pyrimethamine may prove to be very effective
agents against P. knowlesi, both for treatment and prophylaxis.
Future studies should explore the impact of both DHFR and
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Figure 2. Effect of synchrony on drug susceptibility measured across the life cycle using the SYBR Green I method after one or two life cycles. EC50
values for chloroquine (squares), dihydroartemisinin (circles) or pyrimethamine (diamonds) were determined from experiments initiated at the times
shown on the y-axis using synchronized parasites at 1% parasitemia and 1% haematocrit that were incubated for either 27 h (a) or 54 h (b)
for P. knowlesi, and 48 h (c) or 96 h (d) for P. falciparum. Signal window (squares) and assay quality (Z0 factor, circles) (e–h) were determined as in
Figure 1.
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dihydropteroate synthase inhibitors on P. knowlesi metabolism in
depth, the latter requiring specialized growth media sufficiently
depleted of folate and para-aminobenzoic acid,21,22 and so not
tested here.
Transfection reagents
We tested P. knowlesi susceptibility to three common selective
agents used to favour growth of transfected P. falciparum para-
sites harbouring exogenous DNA. The DHFR inhibitor WR99210
was highly potent against P. knowlesi with an EC50 value of
0.16+0.04 nM. Similar to other DHFR inhibitors tested, WR99210
was significantly more potent against P. knowlesi than against
P. falciparum (0.43+0.03 nM; P"0.0003). Blasticidin was 22-fold
less potent against P. knowlesi when compared with P. falciparum
(Table 1) over a single life cycle, which is consistent with a previous
report,7 in which P. knowlesi H strain was grown in rhesus erythro-
cytes. Reduced susceptibility of P. knowlesi to blasticidin prevents
its use as a selectable marker at the concentrations generally used
for transfection studies. Similarly, P. knowlesi was also 3-fold less
susceptible than 3D7 to DSM1 (Table 1); dihydroorotate dehydro-
genase (DHODH)-containing plasmid selection with DSM1 needs to
be conducted at higher concentrations for this species.
P. knowlesi and P. falciparum were both highly susceptible to
the mitochondrial cytochrome b inhibitor atovaquone (Table 1),
but both poorly susceptible to primaquine in vitro with EC50 values
at micromolar concentrations.
DHODH inhibitors
The DHODH enzyme is a newly validated antimalarial target.18,23–25
Several inhibitors of this enzyme have been identified and the two
most advanced, DSM421 and DSM265, are currently in preclinical
and Phase II trials.23,25 Considering the reduced potency of the
transfection reagent DSM1 against P. knowlesi versus P. falciparum,
we tested other DHODH inhibitors against P. knowlesi (Table 2). All
Table 1. Comparison of the antiplasmodial activity against P. knowlesi or P. falciparum, assessed using the SYBR Green I assay, for a set of clinical and
experimental antimalarials exposed over one complete life cycle
Compound
EC50 values (nM)
Fold difference
(P. falciparum/P. knowlesi) Pa
P. knowlesi (A1-H.1),
27 h exposure
P. falciparum (3D7),
48 h exposure
4-Aminoquinolines and amino-alcohols
chloroquine 29.3+4.7 15.9+3.0 0.54 0.0303
amodiaquine 9.3+1.7 5.9+0.6 0.63 0.0662
desethylamodiaquine 12.4+1.4 12.4+3.1 1.00 0.9973
quinine 54.8+3.0 57.9+6.9 1.06 0.7177
mefloquine 10.9+1.1 26.2+4.2 2.40 0.0090
lumefantrine 90.4+13 152+26 1.68 0.0424
piperaquine 21.0+3.1 39.8+4.9 1.90 0.0115
pyronaridine 10.7+1.6 4.4+1.6 0.41 0.0268
ferroquineb 12.2+1.6 4.7+0.6 0.39 0.0068
Endoperoxides
dihydroartemisinin 2.0+0.3 4.2+0.5 2.10 0.0098
artesunate 10.9+1.7 9.0+1.5 0.83 0.4280
OZ439b 6.6+1.4 7.4+1.2 1.12 0.6750
DHFR inhibitors
pyrimethamine 5.1+0.8 54.0+5.0 10.6 ,0.0001
cycloguanil 1.3+0.3 11.8+0.6 9.08 ,0.0001
trimethoprim 265+47 3098+229 11.7 ,0.0001
P218b 4.1+0.7 3.5+0.2 0.85 0.4884
Transfection reagents
WR99210c 0.16+0.04 0.43+0.03 2.69 0.0003
blasticidinc 31684+3485 1413+190 0.04 ,0.0001
DSM1c 509+11 149+5 0.29 ,0.0001
Other
primaquine 3871+887 5627+1195 1.45 0.2847
atovaquone 2.6+0.4 2.3+0.5 0.88 0.6366
EC50 values are reported as mean+ SEM from at least three experiments, and some up to eight repeats, each performed in duplicate.
aP values are calculated by comparing EC50 values for P. falciparum versus P. knowlesi using Student’s two-tailed unpaired t-test.
bThese agents are undergoing development for their potential use as antimalarial agents (http://www.mmv.org/research-development/interactive-
rd-portfolio).
cThese compounds are used in transfection studies with P. falciparum to select for parasites that harbour plasmids carrying drug resistance cassettes.
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compounds were2.7-fold more potent against P. falciparum than
against P. knowlesi whether tested over one or two life cycles.
In particular, DSM265 was 8-fold more potent against P. falciparum
(Table 2). This supports previous observations suggesting that
P. knowlesiwas less susceptible to DHODH inhibitors thanP. falciparum.18
However, in that study the two species were tested under com-
pletely discordant assay conditions. Whether P. knowlesi is less
susceptible than P. falciparum to the effects of DHODH inhibitors
because of differences in enzyme activity, access to the enzyme
or fundamental differences in the biology of these parasites re-
mains to be established. Of note, DSM265 was shown to be about
5-fold more active against P. falciparum field isolates than
Plasmodium vivax field isolates ex vivo, while DSM421 was
equipotent against both species,25 reinforcing the relevance of
using P. knowlesi drug susceptibility testing to inform drug devel-
opment for P. vivax.4
Delayed death effect
Antibacterial agents, such as azithromycin and clindamycin, have
been shown to exert potent activity against P. falciparum in vitro
but only after two complete asexual life cycles (96 h).26 This phe-
nomenon is referred to as the delayed death effect, and has also
been reported for clindamycin against P. knowlesi in vitro.8 In our
experiments, a delayed death effect in P. knowlesi is confirmed for
clindamycin, doxycycline and azithromycin (Table 3). EC50 values
for P. knowlesi were measured over three life cycles (81 h), as add-
itional time was required to resolve the full delayed drug effect in
our experiments using unsynchronized cultures. For P. falciparum
parasites the assay used synchronized parasites, and therefore,
two cycles (96 h) were sufficient to detect the delayed death ef-
fect. Azithromycin was equally potent between species over a sin-
gle life cycle (P"0.4397) and not significantly different in its
delayed death effect (P"0.2514). Similarly, clindamycin had no
measurable effect over a single life cycle in either species but was
very potent against P. knowlesi (15.9 nM) and P. falciparum
(7.0 nM) over 81 and 96 h, respectively. For doxycycline the
delayed death potency for P. knowlesi was much reduced
(2061 nM) relative to P. falciparum (623 nM). We noted that the
Table 2. Susceptibility of P. knowlesi and P. falciparum to three DHODH inhibitors assessed using the SYBR Green I assay
DHODH inhibitor
EC50 (nM), single life cycle EC50 (nM), two life cycles
P. knowlesi, 27 h P. falciparum, 48 h fold difference P. knowlesi, 54 h P. falciparum, 96 h fold difference
DSM1 509+11 149+5 3.4 417+2 91+10 4.6
DSM265 303+15 37+3 8.2 186+11 21+1 8.9
DSM421 194+23 72+5 2.7 123+10 42+4 2.9
All inhibitors were tested in duplicate on three separate occasions from a starting parasitaemia and haematocrit of 1%. The EC50 values are reported
as the mean+ SEM. The fold difference is calculated by dividing the P. knowlesi EC50 value by the P. falciparum EC50 value. For each DSM compound,
the mean P. falciparum EC50 value was significantly lower than the mean P. knowlesi EC50 value when compared over either a single parasite life cycle
or over two life cycles (P0.0018).
Table 3. Delayed death effect of three antibacterial agents against P. knowlesi and P. falciparum assessed using the SYBR Green I assay
Antibacterial
P. knowlesi EC50 (nM) P. falciparum EC50 (nM)
27 h 81 h fold difference 48 h 96 h fold difference
Azithromycin 5662+725 31.9+10 177 6003+323 19.2+4 313
Doxycycline .10000 2061+343 .4.9 .10000 623+148 .16
Clindamycin .10000 15.9+4 .629 .10000 7.0+1.0 .1429
All antibacterial agents were screened in duplicate on at least three separate occasions from a starting parasitaemia and haematocrit of 1%. The
EC50 values are reported as the mean+ SEM. The fold difference for each compound is calculated by dividing the EC50 value after three life cycles (for
P. knowlesi) or two life cycles (for P. falciparum) by the EC50 value measured after a single life cycle exposure.
Table 4. Comparison of the susceptibility of P. knowlesi grown in either
human or macaque red blood cells to selected antimalarial agents as-
sessed using the SYBR Green I assay
Antimalarial
EC50 (nM)
Fold
difference P
human
blood
macaque
blood
Chloroquine 24.6+3.3 42.0+8.1 0.59 0.2114
Dihydroartemisinin 1.9+0.2 4.1+0.7 0.46 0.1250
Quinine 48.0+6.7 54.7+1.4 0.88 0.4303
Mefloquine 11.0+1.5 18.3+0.2 0.60 0.0502
Pyrimethamine 8.9+0.8 13.2+2.7 0.67 0.2940
Antimalarial agents were screened in duplicate on three separate occa-
sions from a starting parasitaemia and haematocrit of 1%. The EC50 val-
ues are reported as the mean+ SEM. The fold difference for each
compound is calculated by dividing the EC50 in human blood by the EC50
value in macaque blood measured after a single life cycle exposure
(27 h).
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delayed death curves did not level out to 0% viability but were
asymptotic at about 25% viability, presumably due to the greater
amount of residual DNA from parasites surviving the first cycle of
growth compared with the chloroquine control wells in which
parasites die in the first cycle. This was corrected for clindamycin
and doxycycline, but not azithromycin, by using a background con-
trol generated for the second cycle only (Figure S4).
Drug susceptibility of P. knowlesi grown in human
versus macaque blood
We assessed the effect of culturing P. knowlesi parasites in human
versus macaque erythrocytes on susceptibility to a subset of anti-
malarials (Table 4). No significant host-specific differences in po-
tency were observed, although it was evident that the EC50 values
were generally higher in parasites grown in macaque erythrocytes
(Table 4). This could be related to higher growth rates of P. knowlesi
parasites in macaque cells, estimated at 5- to 7-fold compared
with 3- to 4-fold in human erythrocytes.6
The P. knowlesi A1-H.1 is descended from a 1964 macaque iso-
late and is assumed to be drug susceptible.27,28 Using identical
growth media and viability readouts, we expected to find EC50 esti-
mates very similar to those for P. falciparum 3D7 for most, if not all,
antimalarials tested. The unexpected differences in susceptibility
to DHFR inhibitors (pyrimethamine, cycloguanil and trimethoprim)
and DHODH inhibitors suggest that important species-specific dif-
ferences in drug responses exist. A recent study reported the in vitro
activity of the 400 compound Malaria Box against P. falciparum 3D7
and showed that 90% were also active against P. knowlesi yH-1
strain.29 Closer examination of those data show that EC50 esti-
mates for 52 compounds were at least 3-fold higher or lower for
P. knowlesi than for P. falciparum.
Conclusions
We have provided detailed validation of a fluorescent assay sys-
tem for drug susceptibility testing in P. knowlesi. This provides an
important new tool for in vitro drug studies in non-P. falciparum
malaria. Significant species-specific differences in susceptibility to
certain compound classes was observed, highlighting the added
value of in vitro screens against additional human malaria patho-
gens. The generalizability of our findings should now be tested in
recent P. knowlesi field isolates from geographically distinct re-
gions of South-East Asia.
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